AIRLINK 80.60 Increased By ▲ 1.19 (1.5%)
BOP 5.26 Decreased By ▼ -0.07 (-1.31%)
CNERGY 4.52 Increased By ▲ 0.14 (3.2%)
DFML 34.50 Increased By ▲ 1.31 (3.95%)
DGKC 78.90 Increased By ▲ 2.03 (2.64%)
FCCL 20.85 Increased By ▲ 0.32 (1.56%)
FFBL 33.78 Increased By ▲ 2.38 (7.58%)
FFL 9.70 Decreased By ▼ -0.15 (-1.52%)
GGL 10.11 Decreased By ▼ -0.14 (-1.37%)
HBL 117.85 Decreased By ▼ -0.08 (-0.07%)
HUBC 137.80 Increased By ▲ 3.70 (2.76%)
HUMNL 7.05 Increased By ▲ 0.05 (0.71%)
KEL 4.59 Decreased By ▼ -0.08 (-1.71%)
KOSM 4.56 Decreased By ▼ -0.18 (-3.8%)
MLCF 37.80 Increased By ▲ 0.36 (0.96%)
OGDC 137.20 Increased By ▲ 0.50 (0.37%)
PAEL 22.80 Decreased By ▼ -0.35 (-1.51%)
PIAA 26.57 Increased By ▲ 0.02 (0.08%)
PIBTL 6.76 Decreased By ▼ -0.24 (-3.43%)
PPL 114.30 Increased By ▲ 0.55 (0.48%)
PRL 27.33 Decreased By ▼ -0.19 (-0.69%)
PTC 14.59 Decreased By ▼ -0.16 (-1.08%)
SEARL 57.00 Decreased By ▼ -0.20 (-0.35%)
SNGP 66.75 Decreased By ▼ -0.75 (-1.11%)
SSGC 11.00 Decreased By ▼ -0.09 (-0.81%)
TELE 9.11 Decreased By ▼ -0.12 (-1.3%)
TPLP 11.46 Decreased By ▼ -0.10 (-0.87%)
TRG 70.23 Decreased By ▼ -1.87 (-2.59%)
UNITY 25.20 Increased By ▲ 0.38 (1.53%)
WTL 1.33 Decreased By ▼ -0.07 (-5%)
BR100 7,629 Increased By 103 (1.37%)
BR30 24,842 Increased By 192.5 (0.78%)
KSE100 72,743 Increased By 771.4 (1.07%)
KSE30 24,034 Increased By 284.8 (1.2%)

Russian COVID-19 vaccine approval imminent, source says Russian

  • Separately, Russia's Interfax news agency cited "an informed source" as saying the vaccine would be registered from Aug. 10-12 and be administered from Aug. 15 onwards.
Published July 29, 2020

MOSCOW: Russia's first potential COVID-19 vaccine will win local regulatory approval in the first half of August and be administered to frontline health workers soon afterwards, a development source close to the matter told Reuters.

A state research facility in Moscow - the Gamaleya Institute - completed early human trials of the adenovirus-based vaccine this month and expects to begin large-scale trials in August.

The vaccine will win regulatory approval from authorities in Russia while that large-scale trial continues, the source said, highlighting Moscow's determination to be the first country in the world to approve a vaccine.

The speed at which Russia is moving to roll out the vaccine has prompted some Western media to question whether Moscow is putting national prestige before solid science and safety.

"(Regulatory) approval will be in the first two weeks of August," the development source said. "August 10 is the expected date, but it will definitely be before August 15. All (trial) results so far are highly positive."

The source added that Russian health workers treating COVID-19 patients will be offered the chance of volunteering to be vaccinated soon after the vaccine receives the regulatory approval.

Separately, Russia's Interfax news agency cited "an informed source" as saying the vaccine would be registered from Aug. 10-12 and be administered from Aug. 15 onwards.

The press service of the Russian Direct Investment Fund (RDIF), which is coordinating and funding Russia's vaccine development efforts, declined to comment, but its head, Kirill Dmitriev, has denied that Russia's vaccine push is compromising safety.

"The Ministry of Health in Russia is following all necessary strict procedures. No corners are being cut," Dmitriev said on Tuesday.

Dmitriev likened what he said was Russia's success in developing a vaccine to the Soviet Union's 1957 launch of Sputnik 1, the world's first satellite.

"Just as Sputnik was the result of very talented Russian scientists ... our vaccine research is based on the work of great Russian scientists," he said.

Britain's National Cyber Security Centre said this month that hackers backed by the Russian state were trying to steal COVID-19 vaccine and treatment research from academic and pharmaceutical institutions around the world. The allegations have been denied by Moscow.

More than 100 possible vaccines are being developed around the world to try to stop the COVID-19 pandemic. At least four are in final Phase III human trials, according to WHO data, including three developed in China and another in Britain.

Comments

Comments are closed.